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Probable Donor-Derived Human 
Adenovirus Type 34 Infection in 2 
Kidney Transplant Recipients From the 
Same Donor
Matthew A. Pettengill,1,2 Tara M. Babu,1 Paritosh Prasad,1 Sally Chuang,1  
Michael G. Drage,1 Marilyn Menegus,1,† Daryl M. Lamson,3 Xiaoyan Lu,4  
Dean Erdman,4 and Nicole Pecora1
1University of Rochester Medical Center, Rochester, New York; 2Thomas Jefferson University, 
Philadelphia, Pennsylvania; 3Wadsworth Center, New York State Department of Health, 
Albany, New York; 4US Centers for Disease Control and Prevention, Atlanta, Georgia
Human adenovirus type 34 (HAdV-34) infection is a recog-
nized cause of transplant-associated hemorrhagic cystitis and, 
in rare cases, tubulointerstitial nephritis. The source of such 
infections is often difficult to assess, that is, whether acquired as 
a primary infection, exposure to a pathogen in the transplanted 
organ, or reactivation of an endogenous latent infection. We 
present here 2 cases of likely transplant-acquired HAdV-34 in-
fection from the same organ donor, manifesting as tubulointer-
stitial nephritis in 1.
Keywords. adenovirus; HAdV-34; kidney transplant; 
 tubulointerstitial nephritis.
Transplant recipients and other immunocompromised patients 
are particularly susceptible to severe disease or death due to 
infection with human adenoviruses (HAdVs), which can affect 
almost any organ system [1–3]. In stem cell transplant patients, 
severe lymphopenia is associated with disseminated HAdV 
infection [3, 4]. Kidney transplant recipients may develop seri-
ous infections, commonly manifesting as hemorrhagic cystitis, 
though tubulointerstitial nephritis has rarely been reported 
[5–9]. Patients develop clinical disease 1 to 3  months after 
transplant [10]. The most common types of HAdV associated 
with serious renal infections are from species B (types 7, 11, 34, 
and 35)  [1, 4, 8, 11, 12]. Although establishing an etiology of 
these infections is difficult, their propensity to occur not long 
after the time of transplant and to affect the kidneys and urinary 
tract has raised the possibility of a donor-derived infection. This 
report describes clinical and laboratory findings from a donor 
and 2 kidney transplant recipients who evidenced transmission 
of infection with HAdV-34 after transplantation.
DONOR
The donor was a 31-year-old male with a history of a seizure 
disorder who presented to an outside hospital after a seizure 
and head trauma complicated by cardiac and respiratory arrest. 
No respiratory illness was noted; however, a computed tomog-
raphy (CT) head scan did demonstrate mucosal thickening in 
the ethmoid sinuses and air fluid levels in the sphenoid sinuses, 
which could suggest recent viral infection. Chest x-ray (CXR) on 
admission noted patchy opacity in the right upper lobe; this was 
improved on repeat CXR on hospital day 2, and CT of the chest 
on hospital day 5 demonstrated only atelectasis. His kidneys were 
transplanted into 2 patients in 1 medical center reported on here. 
The heart, lungs, and liver were all available from this donor for 
transplant. The liver was rejected on biopsy for unknown rea-
sons. The heart and lungs were transplanted at other medical 
centers and, at the date of writing, recipient patients were doing 
well without evidence of adenovirus infection. Note that, to the 
best of our knowledge, serologic tests have not been performed 
on these patients. In addition, the center that transplanted this 
donor’s lungs routinely screens for adenovirus species B/E and C 
when they perform pre- and post-transplant bronchoscopies (3 
of the latter) as part of their routine care (HAdV-34 is a serotype 
of adenovirus B). No specimens tested positive for adenovirus. 
Both centers (heart and lungs) were notified of the potential 
adenovirus transmission and continue to monitor those patients.
PATIENT 1
Patient 1 was a 36-year-old male with end-stage renal disease 
due to sclerosing glomerulonephritis, for which he underwent 
an uncomplicated deceased donor kidney transplant (donor 
CMV IgG negative, recipient CMV IgG positive). He received 
antithymocyte globulin induction. One month after his trans-
plant, he presented to the hospital with 3 days of allograft ten-
derness, hematuria, fever, dysuria, and urinary retention. At 
that time, he was on valganciclovir, trimethoprim/sulfameth-
oxazole, and fluconazole prophylaxis. His immunosuppressive 
regimen consisted of tacrolimus 6  mg daily, mycophenolate 
mofetil 1000 mg twice daily, and prednisone 20 mg daily.
On admission, the patient had a low-grade fever and was 
hemodynamically stable. His physical exam demonstrated sig-
nificant tenderness to palpation over his allograft. Admission 
laboratory values revealed a white blood cell count (WBC) 
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of 5.9 THOU/uL with lymphopenia, a hemoglobin (Hgb) of 
10.7  g/dL, and a platelet count of 166 THOU/uL. His creati-
nine (Cr) was elevated at 1.69  mg/dL (1.15  mg/dL 1  month 
prior, the lowest since transplant). His liver function tests were 
normal. Urine studies showed 660 red blood cells (RBCs) and 
61 WBCs. Computerized tomography abdominal imaging on 
admission showed perinephric stranding consistent with allo-
graft pyelonephritis.
The patient was started on empiric antibiotic therapy for 
presumed bacterial allograft pyelonephritis while the micro-
biologic testing was pending. He initially improved; however, 
on day 3 of hospitalization, he had worsening allograft ten-
derness and high-grade fevers up to 40°C. Repeat CT abdom-
inal imaging showed progressive perinephric stranding and 
allograft edema. Urine and blood cultures were negative. Serum 
was submitted for quantitative HAdV nucleic acid testing (~5 
weeks post-transplantation), which was positive at a level of 
6 × 106 HAdV genome copies/mL. HAdV molecular typing was 
performed by polymerase chain reaction (PCR) amplification 
and sequence analysis of a partial region of the HAdV hexon 
gene and was determined to be HAdV-34 (nucleotide sequence 
similarity score  =  99% compared with reference sequence 
KF268196) [13].
Core biopsy of the allograft kidney revealed sharply demar-
cated zones of tubular necrosis in a pauci-inflammatory back-
ground. High-powered examination revealed residual tubular 
epithelium with textureless “smudge” chromatin and intralumi-
nal necrotic debris. The histologic findings were characteristic 
of HAdV infection and were confirmed by immunohistochem-
istry (Figure 1A and B). The patient was treated with cidofovir 
(dosed at 1 mg/kg 3 times per week) and probenecid, and immu-
nosuppression was concurrently decreased. With treatment, the 
adenovirus viremia cleared up in 29 days (Table 1). Cidofovir 
therapy was well tolerated for 5 weeks and was stopped when 
his viral load became undetectable. His Cr at treatment comple-
tion was 1.5 mg/dL, and no protein was isolated from his urine. 
The patient had rapid resolution of his symptoms and improve-
ment in renal function.
PATIENT 2
The recipient of the donor’s other kidney was a 40-year-old 
male with end-stage renal disease secondary to type 1 diabetes 
mellitus. He received basiliximab induction (CMV IgG donor 
negative, CMV IgG recipient negative). His clinical course 
was complicated by grade 1A cellular rejection, for which he 
received antithymocyte globulin therapy. He presented to the 
hospital 3  months after transplantation with 2  days of fever, 
chills, and malaise. On admission, he was on acyclovir, dapsone, 
and fluconazole prophylaxis. His immunosuppression at that 
time included tacrolimus 5  mg daily, mycophenolate mofetil 
750 mg twice daily, and prednisone 10 mg daily.
On admission, the patient had fever, rigors, and tachycardia. 
His physical exam was unremarkable. Admission laboratory 
tests revealed a WBC of 11.7 THOU/uL with 22% bandemia, 
a Hgb of 7.1 g/dL, and a platelet count of 249 THOU/uL. His 
Cr was elevated from baseline to 1.99 mg/dL. His liver function 
tests were normal. Urine studies showed 9 WBCs and <1 RBC. 
Blood cultures and urine culture were positive for Escherichia 
coli. He improved with targeted antibiotic therapy for urosep-
sis and concurrent decrease in immunosuppression. Given the 
known history of Patient 1, a serum specimen from Patient 2 
was submitted to a commercial laboratory for HAdV nucleic 
acid testing, which was negative.
HADV SERUM NEUTRALIZATION TEST RESULTS
Using pre- and post-transplant serum specimens, it was pos-
sible to evaluate the timing of Patient 1’s exposure to HAdV-
34. Serum HAdV-34–neutralizing antibodies were measured 
against the HAdV-34 prototype strain Compton using a lab-
oratory-developed test based on a standard serum neutraliza-
tion protocol [14] that had been modified for this study to use 
another cell type (A549). Neutralizing antibodies were consid-
ered positive with titers of 10 or greater. Serum from Patient 
1 was negative for neutralizing antibodies both 6 months and 
1  day before transplant (Table 1). However, by 4 weeks after 
A
B
Figure 1. Patient 1 kidney biopsy sections stained with hematoxylin and eosin (A) 
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transplant, he seroconverted to HAdV-34, consistent with 
the PCR findings and indicating that his HAdV-34 infection 
occurred at the time of transplant, either through the donated 
kidney or as a de novo infection.
As serum was available from both the donor and the second 
kidney recipient pre- and post-transplant, it was possible to dif-
ferentiate between these possibilities. Donor serum collected 
1 day before transplant was positive for neutralizing antibod-
ies (titer 320)  to HAdV-34, indicating prior HAdV-34 infec-
tion. Serum collected 1  day before transplant from Patient 2 
was seronegative. However, a serum specimen from Patient 2 
collected 8 weeks after transplant was positive, indicating sero-
conversion to HAdV-34 (Table 1). These findings indicate that 
both Patient 1 and Patient 2 were infected with HAdV-34 either 
at the time of transplant via a donor organ–derived infection 
or shortly thereafter (independently, as a de novo infection). 
Serum from the donor was submitted for quantitative HAdV 
nucleic acid testing but was negative, indicating that the donor 
was not HAdV viremic at the time of organ harvest, although 
latent infection and viremia below the limit of detection could 
not be ruled out. Tissue was not available to assess the presence 
of virus in the transplanted organs.
DISCUSSION
HAdV-34 was first isolated in 1972 from a 17-year-old male pa-
tient who developed fever after receiving a kidney transplant 
[15]. Multiple reports followed of systemic HAdV-34 infections 
among renal transplant recipients and other immunocompro-
mised patients [8, 16, 17], as well as rare reports of acute conjunc-
tivitis [18, 19] in immunocompetent persons. To our knowledge, 
there are no reports that directly document HAdV latency in the 
kidneys. Latency has been documented in lymphatic tissues of 
the oro-gastrointestinal tract for other hAdV types, and hAdV-
34 infection with persistent shedding in the urine of recipients 
of kidney transplants has has been widely documented. Case 
reports of hAdV-34 infection in patients receiving donor kid-
neys have led to speculation that the virus was latent in donor 
kidneys, becoming active in the recipient as a consequence of 
immunological impairment. In preparation for organ transplan-
tation, donors are tested for a variety of infectious diseases (such 
as hepatitis B, hepatitis C, and HIV) that could be transmitted to 
recipients. However, HAdV testing is not required by the Organ 
Procurement and Transplantation Network (OPTN) [20]. The 
source of an HAdV infection in a transplant patient can be dif-
ficult to determine, and de novo infection or reactivation of la-
tent disease may be the most likely explanations. In this instance, 
1 of the 2 kidney recipients (Patient 1)  had disease suggestive 
of HAdV infection within a few weeks after transplantation, 
which prompted testing that confirmed HAdV tubulointersti-
tial nephritis and disseminated viremia. The United Network 
for Organ Sharing (UNOS) was contacted, and the health status 
of the other 2 recipients was ascertained from the respective 
transplant centers. In addition to the kidneys, the donor heart 
and lungs were also transplanted to separate patients, neither 
of whom developed symptomatic HAdV-related disease or re-
quired HAdV diagnostic testing. The confirmed adenovirus in-
fection in the first patient was reported to the OPTN at the time 
it was diagnosed. The second kidney recipient at our institution 
did not have symptoms specifically suggestive of HAdV infec-
tion but was tested for HAdV due to the known positive results 
of Patient 1. Retrospective testing found that the deceased organ 
donor had serological evidence of prior exposure to HAdV-34.
As both kidney recipients were initially seronegative for 
HAdV-34 before transplant and then seroconverted a few 
Table 1. Human Adenovirus PCR and Serum Neutralization Test Results of Transplant Donor and Recipients
 Donor Recipient (Patient 1)a Recipient (Patient 2)
Time Frame HAdV PCR, GC/mL HAdV-34 Nt, Titer HAdV PCR, GC/mL HAdV-34 Nt, Titer HAdV PCR, GC/mL HAdV-34 Nt, Titer
Pretransplant Neg Pos (320) N/A Neg (<10) N/A Neg (<10)
Post-transplant       
Week 1 N/A N/A Neg N/A N/A N/A
Week 2 N/A N/A N/A N/A N/A N/A
Week 3 N/A N/A Pos (4.3×104) N/A N/A N/A
Week 4 N/A N/A Pos (2.8×105) Pos (160) N/A N/A
Week 5 N/A N/A Pos (6.0×106) N/A N/A N/A
Week 6 N/A N/A Pos (4.6×106) N/A N/A N/A
Week 7 N/A N/A Pos (7.6×103) Pos (640) N/A N/A
Week 8 N/A N/A Pos (2.8×103) N/A N/A Pos (80)
Week 9 N/A N/A Pos (236) Pos (1280) N/A N/A
Week 10 N/A N/A Neg N/A N/A N/A
Week 11 N/A N/A Neg N/A N/A N/A
Week 12 N/A N/A N/A N/A Neg N/A
Abbreviations: GC/mL, genome copies per milliliter; N/A, not available; Neg, negative; Nt, serum neutralization titer; Pos, positive.
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weeks later, a possible route of HAdV-34 transmission was 
from the donor to both organ recipients. As the absence of 
specimens positive for HAdV from both the donor and Patient 
2 makes it impossible to strengthen the connection with 
sequencing data, it does remain possible that both recipients 
contracted HAdV-34 infection independent from the environ-
ment. Although to our knowledge there are limited data avail-
able on hAdV-34 seroprevelance, seropositivity to hAdV-35, 
a closely related virus that shows a similar clinical/epidemio-
logical profile to hAdV-34, was found to be uncommon in an 
international study [21]. At least 1 epidemiological survey has 
indicated that HAdV-34 is uncommon in the general popula-
tion [22], making the possibility of acquisition from the envi-
ronment somewhat less likely. The kidney recipient patients 
did not share a room during their hospital stay, but they were 
seen at separate times by some common health care provid-
ers. No other cases of HAdV disease were diagnosed in other 
patients in the hospital wards occupied by the kidney trans-
plant patients described here in the 6 months preceding or in 
the 6 months after their hospital stay. Interestingly, the clinical 
courses of the 2 patients were quite different, which may reflect 
differences in infectious doses from each kidney or differences 
in host resistance to infection. It is also possible that differing 
cross-protection from prior infections with other adenovirus 
serotypes could have contributed to the difference in clinical 
courses between recipients, but this is poorly understood for 
adenoviruses.
Although donor-derived HAdV infections are rare, testing 
for HAdV should be considered in transplant recipients with 
culture-negative pyelonephritis and those who demonstrate 
hemorrhagic cystitis or tubulointerstitial nephritis within a few 
months of transplant.
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